The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Janssen-Cilag; Roche
Research Funding - Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; Janssen-Cilag; Roche
POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.
 
Herve Tilly
Honoraria - Bristol-Myers Squibb; SERVIER
Consulting or Advisory Role - Janssen; Karyopharm Therapeutics; Roche
Travel, Accommodations, Expenses - Roche
 
Christopher Flowers
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Celgene; Denovo Biopharma; Gilead Sciences; Karyopharm Therapeutics; OptumRx; Pharmacyclics/Janssen; Seagen; Spectrum Pharmaceuticals
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); BeiGene (Inst); Celgene (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Immune Design (Inst); Infinity Pharmaceuticals (Inst); Janssen Oncology (Inst); Onyx (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Genentech/Roche; Gilead Sciences
 
Jonathan W. Friedberg
Consulting or Advisory Role - Astellas Pharma; Bayer
Research Funding - Kite, a Gilead company (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Patient on bone marrow microenvironment signals (I)
Travel, Accommodations, Expenses - Roche
 
Charles Herbaux
No Relationships to Disclose
 
Franck Morschhauser
Honoraria - Bristol-Myers Squibb; Celgene; Epizyme; Janssen; Roche; Servier
Consulting or Advisory Role - Gilead Sciences
 
Laurie Helen Sehn
Honoraria - Abbvie; Acerta Pharma; Amgen; Apobiologix; AstraZeneca; Celgene; Gilead Sciences; Janssen-Ortho; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; morphosys; Roche/Genentech; Seagen; Seagen; Takeda; Takeda; Teva; TG Therapeutics
Consulting or Advisory Role - Abbvie; Acerta Pharma; Amgen; Amgen; apobiologix; AstraZeneca; Celgene; Gilead Sciences; Janssen; Karyopharm Therapeutics; Kite, a Gilead company; Lundbeck; Merck; MorphoSys; Roche/Genentech; Seagen; Takeda; Teva; TG therapeutics; TG Therapeutics
Research Funding - Roche/Genentech (Inst)
 
Jeff Porter Sharman
Leadership - US Oncology
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Celgene; Genentech; Pharmacyclics; TG Therapeutics
Research Funding - Acerta Pharma (Inst); Celgene (Inst); Genentech (Inst); Gilead Sciences (Inst); Merck (Inst); Pharmacyclics (Inst); Seagen (Inst); Takeda (Inst); TG Therapeutics (Inst)
Expert Testimony - Gilead Sciences
 
Marek Trneny
Honoraria - Abbvie; Amgen; Bristol-Myers Squibb; Gilead Sciences; Incyte; Janssen; MorphoSys; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Bristol-Myers Squibb; Celgene; Gilead Sciences; Incyte; Janssen; MorphoSys; Roche; Takeda
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb; Gilead Sciences; janssen; Roche; Takeda
 
Calvin Lee
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Gilles A. Salles
Honoraria - Abbvie; Amgen; Celgene; Gilead Sciences; Janssen; Merck; MorphoSys; Novartis; Roche/Genentech; SERVIER; Takeda
Consulting or Advisory Role - Acerta Pharma; Celgene; Epizyme; Gilead Sciences; Janssen; Kite, a Gilead company; Merck; morphosys; Novartis; Pfizer; Roche/Genentech; SERVIER